Shares of Apogee Therapeutics (NASDAQ:APGE) surged approximately 47% on Monday following the announcement that AbbVie (NYSE:ABBV) will acquire the biotech firm in an all-cash transaction valued at $10.9 billion. Under the terms of the agreement, AbbVie will pay $135.11 per share, representing a significant premium over Apogee's recent trading levels.
The acquisition bolsters AbbVie's immunology pipeline with zumilokibart, a long-acting IL-13 antibody currently in late-stage development for atopic dermatitis, commonly known as eczema. The drug is also being investigated for asthma, positioning it as a potential competitor to Sanofi and Regeneron's blockbuster therapy Dupixent.
At $132.69, Apogee shares were trading approximately 1.8% below the offer price, reflecting a deal spread that investors are pricing in due to risks related to regulatory approval, shareholder votes, and the timing of closing. The transaction is expected to close in the third quarter of 2026.
Zumilokibart is designed as an injection administered every three to six months, offering a dosing convenience advantage over Dupixent's every-two-week regimen. This differentiated profile has made Apogee an attractive acquisition target, according to RBC Capital Markets analyst Brian Abrahams, who noted that AbbVie is an ideal buyer to maximize the drug's potential.
In May, Apogee reported positive Phase 2 data for zumilokibart, with 65.9% of patients achieving at least a 75% improvement in eczema severity, as measured by the EASI-75 endpoint. Dermatology expert Dr. Ruth Ann Vleugels highlighted that the treatment required significantly fewer injections compared to current standard care.
The deal includes a termination fee of $381.3 million under certain break scenarios, including a regulatory-failure fee payable by AbbVie. Apogee had previously secured up to $1.3 billion in non-dilutive financing from Blackstone Life Sciences, which included a synthetic royalty structure with a change-of-control buyback option. This arrangement likely facilitated the acquisition by removing future royalty obligations for AbbVie.
Despite the positive market reaction, risks remain. The transaction requires approval from Apogee shareholders and regulatory bodies. Zumilokibart is still an experimental drug, and late-stage trials could encounter setbacks. Additionally, established competitors like Sanofi, Regeneron, and Eli Lilly already have significant scale in inflammatory disease markets. AbbVie has indicated that the acquisition will not contribute to adjusted earnings per share until 2032, underscoring the long-term nature of the investment.
The broader biotech sector also saw gains, with the SPDR S&P Biotech ETF rising about 3.2%. However, Apogee's move was predominantly deal-driven, highlighting the impact of M&A activity on individual stock performance.
